Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Extracts from Cell Suspension Cultures of Strawberry (Fragaria x ananassa Duch): Cytotoxic Effects on Human Cancer Cells.

Lucioli S, Pastorino F, Nota P, Ballan G, Frattarelli A, Fabbri A, Forni C, Caboni E.

Molecules. 2019 May 4;24(9). pii: E1738. doi: 10.3390/molecules24091738.

2.

Microfragmented human fat tissue is a natural scaffold for drug delivery: Potential application in cancer chemotherapy.

Alessandri G, Coccè V, Pastorino F, Paroni R, Dei Cas M, Restelli F, Pollo B, Gatti L, Tremolada C, Berenzi A, Parati E, Brini AT, Bondiolotti G, Ponzoni M, Pessina A.

J Control Release. 2019 May 28;302:2-18. doi: 10.1016/j.jconrel.2019.03.016. Epub 2019 Mar 16.

PMID:
30890444
3.

Spatiotemporal Regulation of Tumor Angiogenesis by Circulating Chromogranin A Cleavage and Neuropilin-1 Engagement.

Dallatomasina A, Gasparri AM, Colombo B, Sacchi A, Bianco M, Daniele T, Esposito A, Pastorino F, Ponzoni M, Marcucci F, Curnis F, Corti A.

Cancer Res. 2019 Apr 15;79(8):1925-1937. doi: 10.1158/0008-5472.CAN-18-0289. Epub 2019 Feb 22.

PMID:
30796053
4.

Increased myocardial 18F-FDG uptake as a marker of Doxorubicin-induced oxidative stress.

Bauckneht M, Pastorino F, Castellani P, Cossu V, Orengo AM, Piccioli P, Emionite L, Capitanio S, Yosifov N, Bruno S, Lazzarini E, Ponzoni M, Ameri P, Rubartelli A, Ravera S, Morbelli S, Sambuceti G, Marini C.

J Nucl Cardiol. 2019 Feb 8. doi: 10.1007/s12350-019-01618-x. [Epub ahead of print]

PMID:
30737636
5.

Overcoming Biological Barriers in Neuroblastoma Therapy: The Vascular Targeting Approach with Liposomal Drug Nanocarriers.

Pastorino F, Brignole C, Di Paolo D, Perri P, Curnis F, Corti A, Ponzoni M.

Small. 2019 Mar;15(10):e1804591. doi: 10.1002/smll.201804591. Epub 2019 Feb 1. Review.

PMID:
30706636
6.

Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma.

Chen L, Pastorino F, Berry P, Bonner J, Kirk C, Wood KM, Thomas HD, Zhao Y, Daga A, Veal GJ, Lunec J, Newell DR, Ponzoni M, Tweddle DA.

Int J Cancer. 2019 Jun 15;144(12):3146-3159. doi: 10.1002/ijc.32058. Epub 2019 Jan 9.

7.

Enhancement of Tumor Homing by Chemotherapy-Loaded Nanoparticles.

Ponzoni M, Curnis F, Brignole C, Bruno S, Guarnieri D, Sitia L, Marotta R, Sacchi A, Bauckneht M, Buschiazzo A, Rossi A, Di Paolo D, Perri P, Gori A, Sementa AR, Emionite L, Cilli M, Tamma R, Ribatti D, Pompa PP, Marini C, Sambuceti G, Corti A, Pastorino F.

Small. 2018 Nov;14(45):e1802886. doi: 10.1002/smll.201802886. Epub 2018 Oct 7.

PMID:
30294852
8.

Targeting Macrophages as a Potential Therapeutic Intervention: Impact on Inflammatory Diseases and Cancer.

Ponzoni M, Pastorino F, Di Paolo D, Perri P, Brignole C.

Int J Mol Sci. 2018 Jul 4;19(7). pii: E1953. doi: 10.3390/ijms19071953. Review.

9.

Glycine N-methylation in NGR-Tagged Nanocarriers Prevents Isoaspartate formation and Integrin Binding without Impairing CD13 Recognition and Tumor Homing.

Corti A, Gasparri AM, Ghitti M, Sacchi A, Sudati F, Fiocchi M, Buttiglione V, Perani L, Gori A, Valtorta S, Moresco RM, Pastorino F, Ponzoni M, Musco G, Curnis F.

Adv Funct Mater. 2017 Sep 26;27(36). pii: 1701245. doi: 10.1002/adfm.201701245.

10.

Doxorubicin Effect on Myocardial Metabolism as a Prerequisite for Subsequent Development of Cardiac Toxicity: A Translational 18F-FDG PET/CT Observation.

Bauckneht M, Ferrarazzo G, Fiz F, Morbelli S, Sarocchi M, Pastorino F, Ghidella A, Pomposelli E, Miglino M, Ameri P, Emionite L, Ticconi F, Arboscello E, Buschiazzo A, Massimelli EA, Fiordoro S, Borra A, Cossu V, Bozzano A, Ibatici A, Ponzoni M, Spallarossa P, Gallamini A, Bruzzi P, Sambuceti G, Marini C.

J Nucl Med. 2017 Oct;58(10):1638-1645. doi: 10.2967/jnumed.117.191122. Epub 2017 Jun 23.

11.

Molecular galactose-galectin association in neuroblastoma cells: An unconventional tool for qualitative/quantitative screening.

Pastorino F, Ponzoni M, Simone G.

Proteomics Clin Appl. 2017 May;11(5-6). doi: 10.1002/prca.201600116. Epub 2017 Feb 6.

PMID:
28066995
12.

Immunotherapy in the Treatment of Human Solid Tumors: Basic and Translational Aspects.

Olive D, Savoldo B, Pastorino F, Castriconi R.

J Immunol Res. 2016;2016:7853028. doi: 10.1155/2016/7853028. Epub 2016 Jun 1. No abstract available.

13.

Discovery of a novel glucose metabolism in cancer: The role of endoplasmic reticulum beyond glycolysis and pentose phosphate shunt.

Marini C, Ravera S, Buschiazzo A, Bianchi G, Orengo AM, Bruno S, Bottoni G, Emionite L, Pastorino F, Monteverde E, Garaboldi L, Martella R, Salani B, Maggi D, Ponzoni M, Fais F, Raffaghello L, Sambuceti G.

Sci Rep. 2016 Apr 28;6:25092. doi: 10.1038/srep25092.

14.

PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance.

Dondero A, Pastorino F, Della Chiesa M, Corrias MV, Morandi F, Pistoia V, Olive D, Bellora F, Locatelli F, Castellano A, Moretta L, Moretta A, Bottino C, Castriconi R.

Oncoimmunology. 2015 Jul 15;5(1):e1064578. eCollection 2016.

15.

A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma: Anti-angiogenic and anti-tumor effects.

Piaggio F, Kondylis V, Pastorino F, Di Paolo D, Perri P, Cossu I, Schorn F, Marinaccio C, Murgia D, Daga A, Raggi F, Loi M, Emionite L, Ognio E, Pasparakis M, Ribatti D, Ponzoni M, Brignole C.

J Control Release. 2016 Feb 10;223:165-177. doi: 10.1016/j.jconrel.2015.12.037. Epub 2015 Dec 29. No abstract available.

PMID:
26742942
16.

Quantification of antimicrobial usage in dairy cows and preweaned calves in Argentina.

González Pereyra V, Pol M, Pastorino F, Herrero A.

Prev Vet Med. 2015 Dec 1;122(3):273-9. doi: 10.1016/j.prevetmed.2015.10.019. Epub 2015 Oct 31.

PMID:
26558514
17.

Anti-Tumor Effects of Bak-Proteoliposomes against Glioblastoma.

Liguori L, Pastorino F, Rousset X, Alfano S, Cortes S, Emionite L, Daga A, Ponzoni M, Lenormand JL.

Molecules. 2015 Sep 1;20(9):15893-909. doi: 10.3390/molecules200915893.

18.

New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.

Di Paolo D, Yang D, Pastorino F, Emionite L, Cilli M, Daga A, Destafanis E, Di Fiore A, Piaggio F, Brignole C, Xu X, Liang C, Gibbons J, Ponzoni M, Perri P.

Oncotarget. 2015 Oct 6;6(30):28774-89. doi: 10.18632/oncotarget.4342.

19.

The Neuronal Pentraxin-2 Pathway Is an Unrecognized Target in Human Neuroblastoma, Which Also Offers Prognostic Value in Patients.

Bartolini A, Di Paolo D, Noghero A, Murgia D, Sementa AR, Cilli M, Pasqualini R, Arap W, Bussolino F, Ponzoni M, Pastorino F, Marchiò S.

Cancer Res. 2015 Oct 15;75(20):4265-71. doi: 10.1158/0008-5472.CAN-15-0649. Epub 2015 Aug 20.

20.

Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion.

Cossu I, Bottoni G, Loi M, Emionite L, Bartolini A, Di Paolo D, Brignole C, Piaggio F, Perri P, Sacchi A, Curnis F, Gagliani MC, Bruno S, Marini C, Gori A, Longhi R, Murgia D, Sementa AR, Cilli M, Tacchetti C, Corti A, Sambuceti G, Marchiò S, Ponzoni M, Pastorino F.

Biomaterials. 2015 Nov;68:89-99. doi: 10.1016/j.biomaterials.2015.07.054. Epub 2015 Aug 1.

21.

Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.

Zuccari G, Milelli A, Pastorino F, Loi M, Petretto A, Parise A, Marchetti C, Minarini A, Cilli M, Emionite L, Di Paolo D, Brignole C, Piaggio F, Perri P, Tumiatti V, Pistoia V, Pagnan G, Ponzoni M.

J Control Release. 2015 Aug 10;211:44-52. doi: 10.1016/j.jconrel.2015.05.286. Epub 2015 May 29.

PMID:
26031842
22.

ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis.

Martinengo C, Poggio T, Menotti M, Scalzo MS, Mastini C, Ambrogio C, Pellegrino E, Riera L, Piva R, Ribatti D, Pastorino F, Perri P, Ponzoni M, Wang Q, Voena C, Chiarle R.

Cancer Res. 2014 Nov 1;74(21):6094-106. doi: 10.1158/0008-5472.CAN-14-0268. Epub 2014 Sep 5.

23.

sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib.

Loi M, Becherini P, Emionite L, Giacomini A, Cossu I, Destefanis E, Brignole C, Di Paolo D, Piaggio F, Perri P, Cilli M, Pastorino F, Ponzoni M.

J Control Release. 2014 Oct 28;192:157-66. doi: 10.1016/j.jconrel.2014.07.009. Epub 2014 Jul 17.

PMID:
25041999
24.

Nanocarrier-mediated targeting of tumor and tumor vascular cells improves uptake and penetration of drugs into neuroblastoma.

Pastorino F, Brignole C, Loi M, Di Paolo D, Di Fiore A, Perri P, Pagnan G, Ponzoni M.

Front Oncol. 2013 Aug 5;3:190. doi: 10.3389/fonc.2013.00190. eCollection 2013.

25.

Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma.

Di Paolo D, Pastorino F, Zuccari G, Caffa I, Loi M, Marimpietri D, Brignole C, Perri P, Cilli M, Nico B, Ribatti D, Pistoia V, Ponzoni M, Pagnan G.

J Control Release. 2013 Sep 28;170(3):445-51. doi: 10.1016/j.jconrel.2013.06.015. Epub 2013 Jun 19.

PMID:
23792118
26.

Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings.

Loi M, Di Paolo D, Soster M, Brignole C, Bartolini A, Emionite L, Sun J, Becherini P, Curnis F, Petretto A, Sani M, Gori A, Milanese M, Gambini C, Longhi R, Cilli M, Allen TM, Bussolino F, Arap W, Pasqualini R, Corti A, Ponzoni M, Marchiò S, Pastorino F.

J Control Release. 2013 Sep 10;170(2):233-41. doi: 10.1016/j.jconrel.2013.04.029. Epub 2013 May 25.

27.

Neuroblastoma tumorigenesis is regulated through the Nm23-H1/h-Prune C-terminal interaction.

Carotenuto M, Pedone E, Diana D, de Antonellis P, Džeroski S, Marino N, Navas L, Di Dato V, Scoppettuolo MN, Cimmino F, Correale S, Pirone L, Monti SM, Bruder E, Zenko B, Slavkov I, Pastorino F, Ponzoni M, Schulte JH, Schramm A, Eggert A, Westermann F, Arrigoni G, Accordi B, Basso G, Saviano M, Fattorusso R, Zollo M.

Sci Rep. 2013;3:1351. doi: 10.1038/srep01351.

28.

Chromogranin A binds to αvβ6-integrin and promotes wound healing in mice.

Curnis F, Gasparri AM, Longhi R, Colombo B, D'Alessio S, Pastorino F, Ponzoni M, Corti A.

Cell Mol Life Sci. 2012 Aug;69(16):2791-803. doi: 10.1007/s00018-012-0955-z. Epub 2012 Mar 14.

PMID:
22415324
29.

Frizzled receptor 6 marks rare, highly tumourigenic stem-like cells in mouse and human neuroblastomas.

Cantilena S, Pastorino F, Pezzolo A, Chayka O, Pistoia V, Ponzoni M, Sala A.

Oncotarget. 2011 Dec;2(12):976-83.

30.

The use of the orthotopic model to validate antivascular therapies for cancer.

Loi M, Di Paolo D, Becherini P, Zorzoli A, Perri P, Carosio R, Cilli M, Ribatti D, Brignole C, Pagnan G, Ponzoni M, Pastorino F.

Int J Dev Biol. 2011;55(4-5):547-55. doi: 10.1387/ijdb.103230ml. Review.

31.

Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma.

Di Paolo D, Ambrogio C, Pastorino F, Brignole C, Martinengo C, Carosio R, Loi M, Pagnan G, Emionite L, Cilli M, Ribatti D, Allen TM, Chiarle R, Ponzoni M, Perri P.

Mol Ther. 2011 Dec;19(12):2201-12. doi: 10.1038/mt.2011.142. Epub 2011 Aug 9.

32.

Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK.

Di Paolo D, Brignole C, Pastorino F, Carosio R, Zorzoli A, Rossi M, Loi M, Pagnan G, Emionite L, Cilli M, Bruno S, Chiarle R, Allen TM, Ponzoni M, Perri P.

Mol Ther. 2011 Jun;19(6):1131-40. doi: 10.1038/mt.2011.54. Epub 2011 Apr 12.

33.

Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects.

Sapra P, Kraft P, Pastorino F, Ribatti D, Dumble M, Mehlig M, Wang M, Ponzoni M, Greenberger LM, Horak ID.

Angiogenesis. 2011 Sep;14(3):245-53. doi: 10.1007/s10456-011-9209-1. Epub 2011 Mar 31.

34.

Targeted drug delivery and penetration into solid tumors.

Corti A, Pastorino F, Curnis F, Arap W, Ponzoni M, Pasqualini R.

Med Res Rev. 2012 Sep;32(5):1078-91. doi: 10.1002/med.20238. Epub 2011 Feb 1. Review.

PMID:
21287572
35.

Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma.

Brignole C, Marimpietri D, Di Paolo D, Perri P, Morandi F, Pastorino F, Zorzoli A, Pagnan G, Loi M, Caffa I, Erminio G, Haupt R, Gambini C, Pistoia V, Ponzoni M.

Cancer Res. 2010 Dec 1;70(23):9816-26. doi: 10.1158/0008-5472.CAN-10-1251. Epub 2010 Oct 8.

36.

Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.

Pastorino F, Loi M, Sapra P, Becherini P, Cilli M, Emionite L, Ribatti D, Greenberger LM, Horak ID, Ponzoni M.

Clin Cancer Res. 2010 Oct 1;16(19):4809-21. doi: 10.1158/1078-0432.CCR-10-1354. Epub 2010 Aug 11.

37.

Enhanced anti-tumor activity of a new curcumin-related compound against melanoma and neuroblastoma cells.

Pisano M, Pagnan G, Dettori MA, Cossu S, Caffa I, Sassu I, Emionite L, Fabbri D, Cilli M, Pastorino F, Palmieri G, Delogu G, Ponzoni M, Rozzo C.

Mol Cancer. 2010 Jun 3;9:137. doi: 10.1186/1476-4598-9-137.

38.

Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.

Loi M, Marchiò S, Becherini P, Di Paolo D, Soster M, Curnis F, Brignole C, Pagnan G, Perri P, Caffa I, Longhi R, Nico B, Bussolino F, Gambini C, Ribatti D, Cilli M, Arap W, Pasqualini R, Allen TM, Corti A, Ponzoni M, Pastorino F.

J Control Release. 2010 Jul 1;145(1):66-73. doi: 10.1016/j.jconrel.2010.03.015. Epub 2010 Mar 24.

PMID:
20346382
39.

Critical role of flanking residues in NGR-to-isoDGR transition and CD13/integrin receptor switching.

Curnis F, Cattaneo A, Longhi R, Sacchi A, Gasparri AM, Pastorino F, Di Matteo P, Traversari C, Bachi A, Ponzoni M, Rizzardi GP, Corti A.

J Biol Chem. 2010 Mar 19;285(12):9114-23. doi: 10.1074/jbc.M109.044297. Epub 2010 Jan 11.

40.

Liposome-mediated therapy of neuroblastoma.

Di Paolo D, Loi M, Pastorino F, Brignole C, Marimpietri D, Becherini P, Caffa I, Zorzoli A, Longhi R, Gagliani C, Tacchetti C, Corti A, Allen TM, Ponzoni M, Pagnan G.

Methods Enzymol. 2009;465:225-49. doi: 10.1016/S0076-6879(09)65012-6.

PMID:
19913170
41.

Recent advances in targeted anti-vasculature therapy: the neuroblastoma model.

Pastorino F, Di Paolo D, Loi M, Becherini P, Caffa I, Zorzoli A, Marimpietri D, Carosio R, Perri P, Montaldo PG, Brignole C, Pagnan G, Ribatti D, Allen TM, Ponzoni M.

Curr Drug Targets. 2009 Oct;10(10):1021-7. Review.

PMID:
19663770
42.

Anti-IL-10R antibody improves the therapeutic efficacy of targeted liposomal oligonucleotides.

Brignole C, Marimpietri D, Pastorino F, Di Paolo D, Pagnan G, Loi M, Piccardi F, Cilli M, Tradori-Cappai A, Arrigoni G, Pistoia V, Ponzoni M.

J Control Release. 2009 Sep 1;138(2):122-7. doi: 10.1016/j.jconrel.2009.05.006. Epub 2009 May 7.

PMID:
19427884
43.

The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.

Pagnan G, Di Paolo D, Carosio R, Pastorino F, Marimpietri D, Brignole C, Pezzolo A, Loi M, Galietta LJ, Piccardi F, Cilli M, Nico B, Ribatti D, Pistoia V, Ponzoni M.

Clin Cancer Res. 2009 Feb 15;15(4):1199-209. doi: 10.1158/1078-0432.CCR-08-2477.

44.

Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.

Pastorino F, Di Paolo D, Piccardi F, Nico B, Ribatti D, Daga A, Baio G, Neumaier CE, Brignole C, Loi M, Marimpietri D, Pagnan G, Cilli M, Lepekhin EA, Garde SV, Longhi R, Corti A, Allen TM, Wu JJ, Ponzoni M.

Clin Cancer Res. 2008 Nov 15;14(22):7320-9. doi: 10.1158/1078-0432.CCR-08-0804.

45.

Drug delivery systems: application of liposomal anti-tumor agents to neuroectodermal cancer treatment.

Di Paolo D, Pastorino F, Brignole C, Marimpietri D, Loi M, Ponzoni M, Pagnan G.

Tumori. 2008 Mar-Apr;94(2):246-53.

PMID:
18564613
46.

Aromatase inhibitors for breast cancer: different structures, same effects?

Ponzone R, Mininanni P, Cassina E, Pastorino F, Sismondi P.

Endocr Relat Cancer. 2008 Mar;15(1):27-36. doi: 10.1677/ERC-07-0249. Review.

PMID:
18310273
47.

Ligand-targeted liposomal therapies of neuroblastoma.

Pastorino F, Marimpietri D, Brignole C, Di Paolo D, Pagnan G, Daga A, Piccardi F, Cilli M, Allen TM, Ponzoni M.

Curr Med Chem. 2007;14(29):3070-8. Review.

PMID:
18220743
48.

Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin.

Pastorino F, Mumbengegwi DR, Ribatti D, Ponzoni M, Allen TM.

J Control Release. 2008 Feb 18;126(1):85-94. doi: 10.1016/j.jconrel.2007.11.010. Epub 2007 Nov 28.

PMID:
18166243
49.

Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis.

Marimpietri D, Brignole C, Nico B, Pastorino F, Pezzolo A, Piccardi F, Cilli M, Di Paolo D, Pagnan G, Longo L, Perri P, Ribatti D, Ponzoni M.

Clin Cancer Res. 2007 Jul 1;13(13):3977-88.

50.

[Environmental hygiene of the surgery suites for the control of surgical wound infection: Italian legislation and international guidelines].

Charrier L, Castella A, Di Legami V, Pastorino F, Farina EC, Argentero PA, Zotti CM; Gruppo di Lavoro Regionale sulle Infezioni Ospedaliere.

Ann Ig. 2006 Nov-Dec;18(6):491-505. Italian.

PMID:
17228607

Supplemental Content

Loading ...
Support Center